切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2024, Vol. 18 ›› Issue (03) : 229 -234. doi: 10.3877/cma.j.issn.1674-0793.2024.03.011

综述

胃癌分子分型的研究进展及相关联系
王欢欢1, 郑少祥1, 郝金锦1, 陈文亮2,()   
  1. 1. 030001 太原,山西医科大学研究生院
    2. 030001 太原,山西医科大学第二医院普通外科
  • 收稿日期:2023-12-18 出版日期:2024-06-01
  • 通信作者: 陈文亮
  • 基金资助:
    山西省自然科学基金资助项目(201801D121320)

Advances and correlation in molecular classification of gastric cancer

Huanhuan Wang1, Shaoxiang Zheng1, Jinjin Hao1, Wenliang Chen2,()   

  1. 1. Graduate Department of Shanxi Medical University, Taiyuan 030001, China
    2. Department of General Surgery, the Second Affiliated Hospital of Shanxi Medical University, Taiyuan 030001, China
  • Received:2023-12-18 Published:2024-06-01
  • Corresponding author: Wenliang Chen
引用本文:

王欢欢, 郑少祥, 郝金锦, 陈文亮. 胃癌分子分型的研究进展及相关联系[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 229-234.

Huanhuan Wang, Shaoxiang Zheng, Jinjin Hao, Wenliang Chen. Advances and correlation in molecular classification of gastric cancer[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(03): 229-234.

胃癌是常见的消化道恶性肿瘤,高度异质性是胃癌诊断和治疗的棘手问题之一。目前对于传统胃癌分型的治疗策略并不完善,因此对于胃癌分子分型的研究是极其必要的。本文回顾了癌症基因组图谱(TCGA)及亚洲癌症研究小组(ACRG)两种里程碑式的分子分型,并从单细胞RNA测序、lncRNA、表观遗传学、免疫浸润等方面进一步阐述胃癌不同的分子分型,阐述每个分型不同的分子特征和生物学行为以及不同分型之间的联系,并探寻其可能作用的基因靶点和机制通路,为改善胃癌患者预后并开展针对特定亚型的靶向治疗提供依据。

Gastric cancer is a common malignant tumor of digestive tract, and its high heterogeneity is one of the thorny problems in the diagnosis and treatment of gastric cancer. At present, the traditional treatment strategies for gastric cancer classification are not perfect, so the research on molecular classification of gastric cancer is extremely necessary. In this paper, two landmark molecular classifications of The Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) were reviewed, and different molecular classifications of recent gastric cancer were further elaborated from the aspects of single-cell RNA sequencing, lncRNA, epigenetics, and immune infiltration. The different molecular characteristics and biological behaviors of each type as well as the relationship between different subtypes were described. The gene targets and mechanism pathways of their action may be explored, which helps improve the outcomes and provides basis for targeted therapy for specific subtypes.

表1 胃癌的几种分子分型及相关联系
[1]
Bian S, Wang Y, Zhou Y, et al. Integrative single-cell multiomics analyses dissect molecular signatures of intratumoral heterogeneities and differentiation states of human gastric cancer[J]. Natl Sci Rev, 2023, 10(6): nwad094.
[2]
Zeng Y, Jin RU. Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer[J]. Semin Cancer Biol, 2022, 86(Pt 3): 566-582.
[3]
Angerilli V, Pennelli G, Galuppini F, et al. Molecular subtyping of gastroesophageal dysplasia heterogeneity according to TCGA/ACRG classes[J]. Virchows Arch, 2022, 481(4): 545-552.
[4]
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014, 513(7517): 202-209.
[5]
Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes[J]. Nat Med, 2015, 21(5): 449-456.
[6]
Wang Q, Xie Q, Liu Y, et al. Clinical characteristics and prognostic significance of TCGA and ACRG classification in gastric cancer among the Chinese population[J]. Mol Med Rep, 2020, 22(2): 828-840.
[7]
Tirino G, Pompella L, Petrillo A, et al. What’s new in gastric cancer: the therapeutic implications of molecular classifications and future perspectives[J]. Int J Mol Sci, 2018, 19(9): 2659.
[8]
Katona BW, Rustgi AK. Gastric cancer genomics: advances and future directions[J]. Cell Mol Gastroenterol Hepatol, 2017, 3(2): 211-217.
[9]
Ooi A, Oyama T, Nakamura R, et al. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization[J]. Hum Pathol, 2017, 61: 58-67.
[10]
Mathiak M, Warneke VS, Behrens HM, et al. Clinicopathologic characteristics of microsatellite instable gastric carcinomas revisited: urgent need for standardization[J]. Appl Immunohistochem Mol Morphol, 2017, 25(1): 12-24.
[11]
Sohn BH, Hwang JE, Jang HJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project[J]. Clin Cancer Res, 2017, 23(15): 4441-4449.
[12]
Corso S, Giordano S. How can gastric cancer molecular profiling guide future therapies?[J]. Trends Mol Med, 2016, 22(7): 534-544.
[13]
Jia X, Chen B, Li Z, et al. Identification of a Four-Gene-Based SERM Signature for prognostic and drug sensitivity prediction in gastric cancer[J]. Front Oncol, 2021, 11: 799223.
[14]
Pietrantonio F, Randon G, Di Bartolomeo M, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: A meta-analysis of randomized clinical trials[J]. ESMO Open, 2021, 6(1): 100036.
[15]
Yohe S, Thyagarajan B. Review of clinical next-generation sequencing[J]. Arch Pathol Lab Med, 2017, 141(11): 1544-1557.
[16]
Deng G, Zhang X, Chen Y, et al. Single-cell transcriptome sequencing reveals heterogeneity of gastric cancer: progress and prospects[J]. Front Oncol, 2023, 13: 1074268.
[17]
Zhang M, Hu S, Min M, et al. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing[J]. Gut, 2021, 70(3): 464-475.
[18]
Baniak N, Senger JL, Ahmed S, et al. Gastric biomarkers: A global review[J]. World J Surg Oncol, 2016, 14(1): 212.
[19]
Kim R, An M, Lee H, et al. Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer[J]. Cancer Discov, 2022, 12(4): 984-1001.
[20]
Chen Y, Cheng WY, Shi H, et al. Classifying gastric cancer using FLORA reveals clinically relevant molecular subtypes and highlights LINC01614 as a biomarker for patient prognosis[J]. Oncogene, 2021, 40(16): 2898-2909.
[21]
Grady WM, Yu M, Markowitz SD. Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer[J]. Gastroenterology, 2021, 160(3): 690-709.
[22]
Pfeifer GP. Defining driver DNA methylation changes in human cancer[J]. Int J Mol Sci, 2018, 19(4): 1166.
[23]
Lian Q, Wang B, Fan L, et al. DNA methylation data-based molecular subtype classification and prediction in patients with gastric cancer[J]. Cancer Cell Int, 2020, 20: 349.
[24]
Weng S, Li M, Deng J, et al. Epigenetically regulated gene expression profiles decipher four molecular subtypes with prognostic and therapeutic implications in gastric cancer[J]. Clin Epigenetics, 2023, 15(1): 64.
[25]
Sato Y, Wada I, Odaira K, et al. Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells[J]. Clin Transl Immunology, 2020, 9(10): e1194.
[26]
Ramos M, Pereira MA, de Mello ES, et al. Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: analysis in western patients after curative-intent surgery[J]. World J Clin Oncol, 2021, 12(8): 688-701.
[27]
Carneiro P, Fernandes MS, Figueiredo J, et al. E-cadherin dysfunction in gastric cancer--cellular consequences, clinical applications and open questions[J]. FEBS Lett, 2012, 586(18): 2981-2989.
[28]
Corso G, Carvalho J, Marrelli D, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer[J]. J Clin Oncol, 2013, 31(7): 868-875.
[29]
Cheng N, Hui DY, Liu Y, et al. Is gastric lymphoepithelioma-like carcinoma a special subtype of EBV-associated gastric carcinoma? New insight based on clinicopathological features and EBV genome polymorphisms[J]. Gastric Cancer, 2015, 18(2): 246-255.
[30]
Fashoyin-Aje L, Donoghue M, Chen H, et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1[J]. Oncologist, 2019, 24(1): 103-109.
[31]
Mehta R, Shah A, Almhanna K. Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: An evidence-based review of place in therapy[J]. Onco Targets Ther, 2018, 11: 6525-6537.
[1] 安杰, 牛云峰, 刘伟. LINC00520 通过miR-519b-3p/HIF1A 轴促进胃癌的侵袭转移[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 430-436.
[2] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[3] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[4] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[5] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[6] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[7] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[8] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[9] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[10] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[11] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[12] 刘海旺, 施海, 尚利峰. 不同吻合器在腹腔镜远端胃癌根治术Roux-en-Y式吻合中的应用对比[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 643-646.
[13] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[14] 王国强, 张纲, 唐建坡, 张玉国, 杨永江. LINC00839 调节miR-17-5p/WEE1 轴对结直肠癌细胞增殖、凋亡和迁移的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 491-499.
[15] 张立俊, 孙存杰, 胡春峰, 孟冲, 张辉. MSCT、DCE-MRI 评估术前胃癌TNM 分期的准确性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 519-523.
阅读次数
全文


摘要